Moderna and Merck’s personalized mRNA cancer therapy clears Phase 3 test, but the numbers still matter
INTerpath-001 met recurrence-free and distant metastasis-free survival endpoints in 1,137 patients, giving individualized mRNA cancer therapy its first positive Phase 3 readout.